There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The chronic myeloid leukemia drug nilotinib ...

More than 11 million adults in the United States are caring for people diagnosed with Alzheimer’s and other forms of dementia ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

For the first time, scientists have developed a drug that works on ... Dementia Diagnostic Markers Change With Time of Day Oct. 2, 2024 — The time of day when blood is taken can affect the ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

About 7 million Americans live with chronic neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral ...

A new study shows that a common glaucoma drug cleared tau build-up and reduced signs of neurodegenerative disease in zebrafish and mice.

Anchor] A candidate substance for a dementia treatment developed by domestic researchers is exported technology to overseas ...

More than one-third of people living with dementia don’t receive a diagnosis at all. Improved and more accessible diagnostic methods would ensure more patients are eligible to receive the drug ...

In late 2022, the results of a groundbreaking stage-three trial for a ‘miracle’ new Alzheimer’s drug, lecanemab ... So why are groundbreaking dementia treatments failing to make the grade?